Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2019: ANNOUNCEMENT: Paris November 28, 2019: Bio-Modeling Systems invited to the PolePharma event "Industrie du futur" to present its collaboration with L2F the EPFL AI company adding a third dimension to AI through the Giotto program.
  • 2019: PRESS RELEASE: Paris November 6, 2019: Bio-Modeling Systems updates its pipeline of therapies, diagnostics, and bioprocesses and invites you to meet its team at BioFit and Polepharma Bio-Production conferences.
  • 2019: ANNOUNCEMENT: Lyon October 17-18, 2019: Bio-Modeling Systems invited at the India-France Knowledge Summit 2 to contribute with its CADI Discovery Platform, the other AI, successfully applied to its Indo-French   therapeutic program UMANG (now Arbuza Regenerate company) addressing  a public health issue concerning 50-100 millions children in India.
  • 2019: PRESS RELEASE: Paris October 1, 2019: Bio-Modeling Systems, the Mechanisms-Based Cosmetics company, is invited to present its CADI™ Discovery platform and 7 outputs at the open Innovation sessions of Cosmetic-360

  • 2019: ANNOUNCEMENT: Lille Juily 2-4, 2019: BMSystems invited as speaker at ANTIMIC 2019: Bacteriophages, Genius and success of precision medicine in infections (ATC HCl) and new tracks for microbiote “surgery” controt with GEMMA microbiota &Autism H2O2O program
  • 2019: PRESS-RELEASE: Paris May 30, 2019 : Manuel GEA, CEO of BMSystems, joins Bolero's Pharma/Health Advisory Board to strengthen their services and accelerate the convergence between clinical research and Real Life Data

  • 2019: ANNOUNCEMENT: Paris May 5, 2019: Bio-Modeling Systems is participating to Neurodegenerative Drug Development Europe Conference in Paris (May 22-23, 2019). Meet us to discover our Alzheimer's and Parkinson’s diseases solutions.
  • 2019: ANNOUNCEMENT: BMSystems will be participating to  Polepharma microbiota conference (the N°1 pharmaceutical cluster in Europe) event to present its GEMMA microbiota &Autism H2O2O program !
  • 2019: PRESS-RELEASE: Paris April  2, 2019: Bio-Modeling Systems, the 14 M€ H2020 GEMMA (Autism and Microbiota) integrative biology partner, announces the release of the public program web site: for the World Autism Awareness Day.
  • 2019-NEW-YEAR PROGRAM: Paris January 24, 2019: In 2019, our founding motto: “Understand disease mechanisms first. Adapted treatments will follow.” is still highly relevant. FRENCH

  • 2018: POSITION PAPER : Paris December 2, 2018: SMART STRATEGY vs. BIG STRATEGY: How Augmented Intelligence, the other AI, addresses the digital “garbage in garbage out” reality and the life complexity

  • 2018: ANNOUNCEMENT: BMSystems invited to present its CADI Discovery platform and achievements at 4 events in Europe,BioFit,-BioWin-Day,COST EC cluster conference, DGA BtoB  

Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

BMSystems history

1989 -1993 Dr. Iris is Group Leader at the CEPH in Paris

  • The CEPH is a Research Institute founded and lead by Nobel laureate Prof. Jean Dausset.
  • Develops methods for high-throughput (HT) sequencing & data integration.
  • Realizes that the links between genome & biological processes are non-linear.
  • One gene = several proteins = multiple interactions = many context-dependent functions.

1993 -1996 Dr. Iris creates & leads Millennium Pharmaceuticals' (USA) HT Sequencing Unit

  • He undertakes the first attempts to carry-out physiological modeling via large scale data integration.
  • He invents & develops the basic tools and methods required for Integrative Biology.
  • Successful completion of two models, leading to the discovery of the UCP2 and EST1 genes and their roles in obesity and hyperglycemia.
  • He realizes that since published information is:
    • incomplete (to an unknown extent),
    • slanted (to an unknown extent),and often
    • incorrect (to an unknown extent).
  • Methodologies to access/generate complementary unbiased information are required

1996-2001 - Dr. Iris is co-founder and C.S.O. of ValiGen SA in Paris

  • He invents, develops and patents 4 new differential gene-expression and genotyping technologies.
  • He invents and develops the computerized data gathering, data mining, clustering and integration tools & technologies necessary for the industrial development of  Integrative Biology / Systems Biology (European "Eureka" grant: 18.6 M Euros).
  • He finalizes the Bio-Graph™ analytical platform based on the "positive selection" concept.
  • He develops the Tamoxifen Resistance model with Bio-Graph™.
  • He identifies the limitations of this analytical platform.

1999-2001 - Dr. Iris meets Mr. M.Gea and Dr. G.Dine

  • Dr. Iris meets M.Gea and Prof. G.Dine, founding members of Centrale-Santé.
  • Dr. François Iris becomes a member of Centrale-Santé's Directorate, the Healthcare & Biotech Think Tank of the Centrale's alumni's Association.
  • He decides to abandon the Bio-Graph™  platform and starts working on a second Generation analytical platform (CADI™) based on the negative selection concept.
  • He starts to work on the first version of the Creutzfeldt-Jakob Disease model. 

2002-2003 -  Dr. Iris, M. Gea and Dr. Dine initiate the BMSystems project

  • Conception of the first European private biotech company specialized in Predictive Integrative biology / Systems Biology.
  • Paul-Henri Lampe, and Pablo Santamaria, members of Centrale-Santé Think Tank, decide to join the project.
  • Development of the CADI™ analytical platform.
  • Four new models completed (FGF4-driven fibroblast differentiation, hypercholesterolemia, Chronic Fatigue Syndrome, Creutzfeldt Jakob disease) two of which are undergoing independent biological evaluation.

2004 - The company is created and starts business operations

  •  Independent Private Company incorporated in 2004. 100% owned by its founders.
  • Profitable since 2006, thanks to our recurrent clients.
  • We only sell the results of the R&D programs, not our proprietary technologies.
  • 100% biology driven company focused on discovery, and critical high impact decisions making
  • A unique proprietary CADI™ Knowledge Database of mechanisms & interactions.
  • Not domain-dependent, but information-dependent. Markets: Pharma, Cosmetics, Nutrition, Health Technologies, Connected health,
  • Highly productive 24 vFTE* of which 9 vFTE on CADI™ Discovery programs only.
  • Strong & long term strategic R&D collaborations (>100 people collaborating).
  • Dual business model : Contractual or Collaborative R&D programs.
  • External valorization of our collaborative R&D programs through out-licensing or spin-off.
  • Outstanding internal pipeline of programs ready for collaborations.
  • 1 therapeutic spin-off and 1 exclusive out-licence, 4 issued patents, 10 publications.
Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology Mechanisms-Based Medicine company that delivers ?>